journal article·2021-03-12Open access

Automated PET-RAFT Polymerization toward Pharmaceutical Amorphous Solid Dispersion Development

Rahul Upadhya, Ashish Punia, Mythili J. Kanagala, Lina Liu, Matthew Lamm, Timothy A. Rhodes, Adam J. Gormley

ACS Applied Polymer Materials· Volume 3· Issue 3

Abstract

In pharmaceutical oral drug delivery development, about 90% of drugs in the pipeline have poor aqueous solubility leading to severe challenges with oral bioavailability and translation to effective and safe drug products. Amorphous solid dispersions (ASDs) have been utilized to enhance the oral bioavailability of poorly soluble active pharmaceutical ingredients (APIs). However, a limited selection of regulatory-approved polymer excipients exists for the development and further understanding of tailor-made ASDs. Thus, a significant need exists to better understand how polymers can be designed to interact with specific API moieties. Here, we demonstrate how an automated combinatorial library approach can be applied to the synthesis and screening of polymer excipients for the model drug probucol. We synthesized a library of 25 random heteropolymers containing one hydrophilic monomer (2-hydroxypropyl acrylate (HPA)) and four hydrophobic monomers at varied incorporation. The performance of ASDs made by a rapid film casting method was evaluated by dissolution using ultra-performance liquid chromatography (UPLC) sampling at various time points. This combinatorial library and rapid screening strategy enabled us to identify a relationship between polymer hydrophobicity, monomer hydrophobic side group geometry, and API dissolution performance. Remarkably, the most effective synthesized polymers displayed slower drug release kinetics compared to industry standard polymer excipients, showing the ability to modulate the drug release profile. Future coupling of high throughput polymer synthesis, high throughput screening (HTS), and quantitative modeling would enable specification of designer polymer excipients for specific API functionalities.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Analytical Chemistry and Chromatography · Innovative Microfluidic and Catalytic Techniques Innovation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States

Preformulation Sciences, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States

Funding

Division of Chemical, Bioengineering, Environmental, and Transport Systems · National Institute of General Medical Sciences · New Jersey Commission on Cancer Research

References (72)

Show source-provided references
1. 10.1021/acs.bioconjchem.7b0064610.1021/acs.bioconjchem.7b00646 ↗
2. 10.1186/s40824-016-0083-110.1186/s40824-016-0083-1 ↗
3. 10.1111/j.2042-7158.2010.01030.x10.1111/j.2042-7158.2010.01030.x ↗
4. 10.1021/cr940208110.1021/cr9402081 ↗
5. 10.1021/ar950170u10.1021/ar950170u ↗
6. 10.1002/anie.19962288110.1002/anie.199622881 ↗
7. 10.1038/nrd.2017.23210.1038/nrd.2017.232 ↗
8. 10.2174/15680261079023223310.2174/156802610790232233 ↗
9. 10.1016/j.drudis.2013.02.00710.1016/j.drudis.2013.02.007 ↗
10. 10.1016/j.ijpharm.2017.10.05110.1016/j.ijpharm.2017.10.051 ↗
11. 10.1021/acs.molpharmaceut.9b0060110.1021/acs.molpharmaceut.9b00601 ↗
12. 10.1002/jps.2207410.1002/jps.22074 ↗
13. 10.1016/j.addr.2015.12.01010.1016/j.addr.2015.12.010 ↗
14. 10.1208/s12249-015-0425-710.1208/s12249-015-0425-7 ↗
15. 10.1021/bm401431t10.1021/bm401431t ↗
16. 10.1021/acs.macromol.7b0037210.1021/acs.macromol.7b00372 ↗
17. 10.1021/acs.molpharmaceut.7b0045810.1021/acs.molpharmaceut.7b00458 ↗
18. 10.1021/ma501839s10.1021/ma501839s ↗
19. 10.1021/acsbiomaterials.5b0023410.1021/acsbiomaterials.5b00234 ↗
20. 10.1021/acscentsci.6b0026810.1021/acscentsci.6b00268 ↗
21. 10.1016/S0928-0987(00)00167-610.1016/S0928-0987(00)00167-6 ↗
22. 10.1016/j.biopha.2004.02.00110.1016/j.biopha.2004.02.001 ↗
23. 10.1016/j.ijpharm.2008.04.04210.1016/j.ijpharm.2008.04.042 ↗
24. 10.1016/j.ijpharm.2018.01.02510.1016/j.ijpharm.2018.01.025 ↗
25. 10.1016/j.ejps.2016.12.03510.1016/j.ejps.2016.12.035 ↗
26. López-Cebral R. · J. Mater. Sci.: Mater. Electron. · 2018 · 29 · 1
27. 10.1016/j.cej.2017.07.02210.1016/j.cej.2017.07.022 ↗
28. 10.1016/j.carbpol.2015.09.07210.1016/j.carbpol.2015.09.072 ↗
29. 10.1016/j.carbpol.2020.11582810.1016/j.carbpol.2020.115828 ↗
30. 10.1021/acs.molpharmaceut.6b0101310.1021/acs.molpharmaceut.6b01013 ↗
31. 10.1016/j.xphs.2017.02.02110.1016/j.xphs.2017.02.021 ↗
32. 10.1021/acs.molpharmaceut.7b0044110.1021/acs.molpharmaceut.7b00441 ↗
33. 10.1021/acs.molpharmaceut.8b0063310.1021/acs.molpharmaceut.8b00633 ↗
34. 10.1126/science.251.4996.88710.1126/science.251.4996.887 ↗
35. 10.1002/pola.2837810.1002/pola.28378 ↗
36. 10.1002/mabi.20030007910.1002/mabi.200300079 ↗
37. 10.1016/j.carbpol.2004.03.00710.1016/j.carbpol.2004.03.007 ↗
38. 10.1002/anie.20171104410.1002/anie.201711044 ↗
39. 10.1021/jacs.9b0989910.1021/jacs.9b09899 ↗
40. 10.1039/C7CS00587C10.1039/C7CS00587C ↗
41. 10.1021/acs.macromol.8b0186410.1021/acs.macromol.8b01864 ↗
42. 10.1021/acsomega.9b0238310.1021/acsomega.9b02383 ↗
43. 10.1021/acs.macromol.6b0247410.1021/acs.macromol.6b02474 ↗
44. 10.1021/acs.molpharmaceut.9b0046810.1021/acs.molpharmaceut.9b00468 ↗
45. 10.1002/anie.20171110510.1002/anie.201711105 ↗
46. 10.1021/ma502120910.1021/ma5021209 ↗
47. 10.1002/anie.20160011210.1002/anie.201600112 ↗
48. 10.1021/ja501745g10.1021/ja501745g ↗
49. 10.1039/C7PY00007C10.1039/C7PY00007C ↗
50. 10.1039/C7PY00442G10.1039/C7PY00442G ↗
51. 10.1021/acs.macromol.6b0158110.1021/acs.macromol.6b01581 ↗
52. 10.1021/acs.macromol.9b0192310.1021/acs.macromol.9b01923 ↗
53. Tamasi M. · Adv. Intell. Syst. · 2020 · 2 · 110.1002/aisy.201900126 ↗
54. 10.1002/marc.20190052810.1002/marc.201900528 ↗
55. 10.1007/s12221-017-6707-910.1007/s12221-017-6707-9 ↗
56. 10.1021/ma800469p10.1021/ma800469p ↗
57. 10.1021/acs.macromol.6b0021510.1021/acs.macromol.6b00215 ↗
58. 10.1039/C9CP04195H10.1039/C9CP04195H ↗
59. 10.1002/jps.2275010.1002/jps.22750 ↗
60. 10.1016/j.pcrysgrow.2016.07.00110.1016/j.pcrysgrow.2016.07.001 ↗
61. 10.1021/acs.molpharmaceut.5b0083710.1021/acs.molpharmaceut.5b00837 ↗
62. 10.1016/0378-5173(94)90180-510.1016/0378-5173(94)90180-5 ↗
63. 10.1208/s12249-013-9971-z10.1208/s12249-013-9971-z ↗
64. 10.1080/07373937.2010.51984010.1080/07373937.2010.519840 ↗
65. 10.1016/S0032-3861(01)00358-510.1016/S0032-3861(01)00358-5 ↗
66. 10.1080/1083745080224484310.1080/10837450802244843 ↗
67. 10.1021/acs.jpca.9b0079210.1021/acs.jpca.9b00792 ↗
68. 10.1016/j.ijpharm.2016.12.02710.1016/j.ijpharm.2016.12.027 ↗
69. 10.1021/jacs.5b0590310.1021/jacs.5b05903 ↗
70. 10.1021/acsmacrolett.8b0081310.1021/acsmacrolett.8b00813 ↗
71. 10.1021/mz400311210.1021/mz4003112 ↗
72. 10.1038/s41586-019-1881-010.1038/s41586-019-1881-0 ↗